WuXi Nextcode, a Shanghai, China- Cambridge, Massachusetts- and Reykjavik, Iceland-based contract genomics organization (CGO) building a global standard platform for genomic data, closed a $75m Series B financing.
The round was co-led by Temasek and Yunfeng Capital with participation from Amgen Ventures, a corporate venture capital fund established by Amgen Inc., and 3W Partners.
The company will use the funds to advance the commercialization of its consumer solutions for the China market and to expand its capabilities in artificial intelligence and deep learning.
Led by Hannes Smarason, CEO, and Dr. Ge Li, chairman of WuXi Nextcode and founder and chairman of WuXi AppTec, WuXi Nextcode is building a global standard platform for genomic data serving population genomics, precision medicine, diagnostics and wellness initiatives and enterprises using the genome to improve health. Capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by proven and used technology for organizing, mining and sharing genome sequence data. The company is also applying the same capabilities to advance a growing range of sequence-based tests and scans in China.